Methamphetamine Treatment Project Corporate Authors: M. Douglas Anglin PhD, Joseph Balabis BA, Richard Bradway, Alison Hamilton Brown PhD, Cynthia Burke PhD, Darrell Christian PhD, Judith Cohen PhD, MPH, Florentina Cosmineanu MS, Alice Dickow BA, Melissa Donaldson, Yvonne Frazier, Thomas E. Freese PhD, Cheryl Gallagher MA, Gantt P. Galloway PharmD, Vikas Gulati BS, James Herrell PhD, MPH, Kathryn Horner BA, Alice Huber PhD, Martin Y Iguchi PhD, Russell H. Lord, EdD, Michael J. McCann MA, Sam Minsky MFT, Pat Morrisey MA, MFT, Jeanne Obert MFT, MSM, Susan Pennell MA, Chris Reiber PhD, MPH, Norman Rodrigues, Jr, Janice Stalcup MSN, Dr PH, S Alex Stalcup MD, Ewa S. Stamper PhD., Janice Stimson, PsyD, Sarah Turcotte Manser MA, Denna Vandersloot MEd, Ahndrea Weiner MS, MFT, Kathryn Woodward BA, Joan Zweben PhD.
Psychopathology in methamphetamine-dependent adults 3 years after treatment
Article first published online: 22 JUN 2009
© 2009 Australasian Professional Society on Alcohol and other Drugs
Drug and Alcohol Review
Volume 29, Issue 1, pages 12–20, January 2010
How to Cite
GLASNER-EDWARDS, S., MOONEY, L. J., MARINELLI-CASEY, P., HILLHOUSE, M., ANG, A., RAWSON, R. A. and THE METHAMPHETAMINE TREATMENT PROJECT CORPORATE AUTHORS (2010), Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug and Alcohol Review, 29: 12–20. doi: 10.1111/j.1465-3362.2009.00081.x
Suzette Glasner-Edwards PhD, Larissa J. Mooney MD, Patricia Marinelli-Casey PhD, Maureen Hillhouse PhD, Alfonso Ang PhD, Richard A. Rawson PhD, the Methamphetamine Treatment Project Corporate Authors, UCLA Integrated Substance Abuse Programs
- Issue published online: 6 JAN 2010
- Article first published online: 22 JUN 2009
- Received 14 July 2008; accepted for publication 6 February 2009.
- clinical course;
- treatment outcome
Introduction and Aims. Although psychiatric symptoms are frequently observed in methamphetamine (MA) users, little is known about the prevalence of psychiatric disorders in MA-dependent individuals. This is the first study to examine the association of psychiatric disorders with substance use and psychosocial functioning in a large sample of MA users 3 years after treatment. We predicted that psychiatric diagnoses and severity would be associated with substance use and poorer overall functioning over the 3 year post-treatment course. Design and Methods. Participants (N = 526) received psychosocial treatment for MA dependence as part of the Methamphetamine Treatment Project and were reassessed for psychosocial functioning and substance use at a mean of 3 years after treatment initiation. DSM-IV psychiatric diagnoses were assessed at follow-up using the Mini-International Neuropsychiatric Interview. Psychosocial functioning was assessed using the Addiction Severity Index. Results. Overall, 48.1% of the sample met criteria for a current or past psychiatric disorder other than a substance use disorder. Consistent with prior reports from clinical samples of cocaine users, this rate was largely accounted for by mood disorders, anxiety disorders and antisocial personality. Those with an Axis I psychiatric disorder evidenced increased MA use and greater functional impairment over time relative to those without a psychiatric disorder. Discussion and Conclusions. This initial investigation of psychiatric diagnoses in MA users after treatment indicates elevated rates of Axis I and II disorders in this population and underscores the need for integrated psychiatric assessment and intervention in drug abuse treatment settings.[Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA, The Methamphetamine Treatment Project Corporate Authors. Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev 2009]